Generics

Taro Pharmaceutical is introducing its first specialty generic, a therapeutic equivalent to Ferriprox.

For the year ended July 2020, IQVIA data showed U.S. sales of roughly $3.8 billion for Tecfidera.

Brand and generic sales for Precedex in 0.9% sodium chloride injection were $210 million for the most recent 12 months ended June 2020, according to IQVIA.

Salix will maintain market exclusivity for Xifaxan (rifaximin) 200 mg and 550 mg tablets until 2028.

Camber's generic Tecfidera provides a treatment for relapsing forms of multiple sclerosis.

Hikma said it now expects to receive FDA approval for its generic Advair Diskus in early 2021.

Divalproex sodium ER tablets had a market value of approximately $130 million, according to IQVIA July 2020 data.

Zydus Cadila’s generic K-Dur will be available in dosage strengths of 750 mg and 1,500 mg.

Tripoint will commercialize SPARC's Elepsia XR tablets for five years, with the option to extend the agreement further.

Dr. Reddy's will be able to sell volume-limited amounts of generic lenalidomide capsules after March 2022, and an unlimited volume beginning Jan. 31, 2026.

Liposomal doxorubicin injection had a market value of approximately $124 million for the 12 months ended July 2020, according to IQVIA.

Prednisone tablets have a market value of roughly $12 million, according to IQVIA July 2020 data.